Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model
- 30 March 2023
- journal article
- research article
- Published by Elsevier in Advances in Medical Sciences
- Vol. 68 (1) , 157-168
Abstract
No abstract availableKeywords
Funding Information
- Rafsanjan University of Medical Sciences
This publication has 53 references indexed in Scilit:
- A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to BedsideClinical Cancer Research, 2013
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Short‐term Therapy with Celecoxib and Lansoprazole Modulates Th1/ Th2 Immune Response in Human Gastric MucosaHelicobacter, 2010
- PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cellsBlood, 2010
- Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cellsToxicology and Applied Pharmacology, 2007
- Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxibJournal of Biomedical Science, 2007
- Short‐term dietary administration of celecoxib enhances the efficacy of tumor lysate‐pulsed dendritic cell vaccines in treating murine breast cancerInternational Journal of Cancer, 2005
- Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant GliomaCancer Research, 2004
- Activated human dendritic cells express inducible cyclo‐oxygenase and synthesize prostaglandin E2 but not prostaglandin D2Immunology & Cell Biology, 2004
- Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.Journal of Experimental Medicine, 1995